PURPOSE: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other options that complement the induction regimen with favorable toxicity are needed. PATIENTS AND METHODS: The phase III, double-blind, placebo-controlled TOURMALINE-MM4 study randomly assigned (3:2) patients with NDMM not undergoing ASCT who achieved better than or equal to partial response after 6-12 months of standard induction therapy to receive the oral proteasome inhibitor (PI) ixazomib or placebo on days 1, 8, and 15 of 28-day cycles as maintenance for 24 months. The primary endpoint was PFS since time of randomization. RESULTS: Patients were randomly assigned to receive ixazomib (n = 425) or placebo (n = 281). TOURMALINE-MM4 met its primary endpoint with a 34.1% reduction in risk of progression or death with ixazomib versus placebo (median PFS since randomization, 17.4 v 9.4 months; hazard ratio [HR], 0.659; 95% CI, 0.542 to 0.801; P < .001; median follow-up, 21.1 months). Ixazomib significantly benefitted patients who achieved complete or very good partial response postinduction (median PFS, 25.6 v 12.9 months; HR, 0.586; P < .001). With ixazomib versus placebo, 36.6% versus 23.2% of patients had grade ≥ 3 treatment-emergent adverse events (TEAEs); 12.9% versus 8.0% discontinued treatment because of TEAEs. Common any-grade TEAEs included nausea (26.8% v 8.0%), vomiting (24.2% v 4.3%), and diarrhea (23.2% v 12.3%). There was no increase in new primary malignancies (5.2% v 6.2%); rates of on-study deaths were 2.6% versus 2.2%. CONCLUSION: Ixazomib maintenance prolongs PFS with no unexpected toxicity in patients with NDMM not undergoing ASCT. To our knowledge, this is the first PI demonstrated in a randomized clinical trial to have single-agent efficacy for maintenance and is the first oral PI option in this patient population.
- MeSH
- antitumorózní látky škodlivé účinky terapeutické užití MeSH
- doba přežití bez progrese choroby MeSH
- dvojitá slepá metoda MeSH
- glycin škodlivé účinky analogy a deriváty terapeutické užití MeSH
- inhibitory proteasomu škodlivé účinky terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom farmakoterapie MeSH
- placeba MeSH
- senioři MeSH
- sloučeniny boru škodlivé účinky terapeutické užití MeSH
- transplantace kmenových buněk MeSH
- udržovací chemoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- antitumorózní látky MeSH
- glycin MeSH
- inhibitory proteasomu MeSH
- ixazomib MeSH Prohlížeč
- placeba MeSH
- sloučeniny boru MeSH
Babesiosis is a tick-transmitted zoonosis caused by apicomplexan parasites of the genus Babesia. Treatment of this emerging malaria-related disease has relied on antimalarial drugs and antibiotics. The proteasome of Plasmodium, the causative agent of malaria, has recently been validated as a target for anti-malarial drug development and therefore, in this study, we investigated the effect of epoxyketone (carfilzomib, ONX-0914 and epoxomicin) and boronic acid (bortezomib and ixazomib) proteasome inhibitors on the growth and survival of Babesia. Testing the compounds against Babesia divergens ex vivo revealed suppressive effects on parasite growth with activity that was higher than the cytotoxic effects on a non-transformed mouse macrophage cell line. Furthermore, we showed that the most-effective compound, carfilzomib, significantly reduces parasite multiplication in a Babesia microti infected mouse model without noticeable adverse effects. In addition, treatment with carfilzomib lead to an ex vivo and in vivo decrease in proteasome activity and accumulation of polyubiquitinated proteins compared to untreated control. Overall, our results demonstrate that the Babesia proteasome is a valid target for drug development and warrants the design of potent and selective B. divergens proteasome inhibitors for the treatment of babesiosis.
- Klíčová slova
- Babesia, Carfilzomib, Cytotoxicity, Epoxyketone, Proteasome,
- MeSH
- Babesia microti účinky léků genetika růst a vývoj MeSH
- Babesia účinky léků genetika růst a vývoj MeSH
- babezióza farmakoterapie MeSH
- buněčné linie MeSH
- inhibitory proteasomu aplikace a dávkování škodlivé účinky farmakologie terapeutické užití MeSH
- kyseliny boronové farmakologie MeSH
- makrofágy účinky léků parazitologie MeSH
- modely nemocí na zvířatech MeSH
- myši MeSH
- oligopeptidy farmakologie MeSH
- proteasomový endopeptidasový komplex účinky léků MeSH
- proteom účinky léků genetika MeSH
- systémy cílené aplikace léků * MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- validační studie MeSH
- Názvy látek
- carfilzomib MeSH Prohlížeč
- epoxomicin MeSH Prohlížeč
- inhibitory proteasomu MeSH
- kyseliny boronové MeSH
- oligopeptidy MeSH
- proteasomový endopeptidasový komplex MeSH
- proteom MeSH
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as a first-line therapy in combination with an alkylating agent and a corticosteroid. Furthermore, bortezomib has also been approved as a second-line therapy for mantle cell lymphoma. In this chapter, the focus is on the current clinical research on bortezomib, its adverse effects, and the resistance of multiple myeloma patients to bortezomib-based therapy. The various applications of bortezomib in different diseases and recent advances in the development of a new generation of inhibitors that target the proteasome or other parts of the ubiquitin-proteasome system are also reviewed.
- MeSH
- bortezomib MeSH
- inhibitory proteasomu škodlivé účinky chemie farmakologie terapeutické užití MeSH
- klinické zkoušky jako téma MeSH
- kyseliny boronové škodlivé účinky chemie farmakologie terapeutické užití MeSH
- lidé MeSH
- nádory farmakoterapie enzymologie MeSH
- proteasomový endopeptidasový komplex imunologie metabolismus MeSH
- pyraziny škodlivé účinky chemie farmakologie terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- bortezomib MeSH
- inhibitory proteasomu MeSH
- kyseliny boronové MeSH
- proteasomový endopeptidasový komplex MeSH
- pyraziny MeSH